Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Reirradiation With NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT04505267 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04505267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04505267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Reirradiation With NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 10, 2021
Completion date
March 31, 2028
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent lung non-small cell carcinoma, stage i lung cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage ii lung cancer ajcc v8, stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, unresectable lung non-small cell carcinoma